Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30400441 | 1.00 | HTR6 (0.41) | HTR6GPR119USP30MMP2MMP13 | |
| SCHEMBL26176372 | 0.77 | PTPN11 (0.41) | HTR6GPR119MMP2MMP13 | |
| SCHEMBL30399794 | 0.77 | PTPN11 (0.41) | HTR6GPR119MMP2MMP13 | |
| SCHEMBL30623425 | 0.72 | MEN1 (0.46) | GPR119USP30HDAC1HDAC8HDAC6 | |
| SCHEMBL2187569 | 0.72 | MEN1 (0.46) | GPR119USP30HDAC1HDAC8HDAC6 | |
| SCHEMBL1221984 | 0.69 | HRH3 (0.51) | GPR119USP30HDAC1HDAC8HDAC6 | |
| SCHEMBL29562510 | 0.69 | HRH3 (0.51) | GPR119USP30HDAC1HDAC8HDAC6 | |
| SCHEMBL24723202 | 0.68 | MET (0.48) | HTR6GPR119CCNCCDK8STS | |
| SCHEMBL1048604 | 0.68 | BRD4 (0.43) | HTR6GPR119USP30STSTGFBR1 | |
| SCHEMBL31694099 | 0.68 | ALK (0.42) | GPR119USP30HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | TENARX, INC. | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192686-A1 | 1H-PYRROLO[2,3-B]PYRIDINES AND PREPARATION AND USES THEREOF | DYRK1A, DYRK1B, DYRK2 | HTR6 2039/4885GPR119 697/4885USP30 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.